Oakworth Capital Inc. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 1.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 207,024 shares of the biopharmaceutical company’s stock after buying an additional 2,754 shares during the quarter. Pfizer makes up about 1.8% of Oakworth Capital Inc.’s investment portfolio, making the stock its 13th largest holding. Oakworth Capital Inc.’s holdings in Pfizer were worth $7,504,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Peregrine Asset Advisers Inc. raised its stake in shares of Pfizer by 0.5% in the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC increased its position in Pfizer by 0.8% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 50 shares during the period. Stone House Investment Management LLC increased its position in Pfizer by 1.0% in the 2nd quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 72 shares during the period. Highland Private Wealth Management increased its position in Pfizer by 0.8% in the 2nd quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock worth $304,000 after buying an additional 76 shares during the period. Finally, Autus Asset Management LLC increased its position in Pfizer by 1.2% in the 2nd quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 78 shares during the period. Institutional investors and hedge funds own 71.16% of the company’s stock.
Shares of Pfizer stock opened at $36.27 on Thursday. Pfizer Inc. has a fifty-two week low of $31.67 and a fifty-two week high of $39.43. The firm has a market capitalization of $216,267.59, a P/E ratio of 10.33, a PEG ratio of 2.05 and a beta of 0.91. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. Pfizer’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.47 EPS. research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer announced that its Board of Directors has approved a stock buyback plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.
PFE has been the topic of several recent analyst reports. Morningstar set a $38.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. UBS set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research report on Wednesday, December 27th. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a research report on Wednesday, January 24th. Finally, Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $39.40.
In related news, insider Mikael Dolsten sold 13,986 shares of the business’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $35.85, for a total value of $501,398.10. Following the sale, the insider now owns 120,884 shares of the company’s stock, valued at approximately $4,333,691.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Charles H. Hill sold 42,393 shares of the business’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total value of $1,515,973.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 248,037 shares of company stock worth $9,064,785. 0.06% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://ledgergazette.com/2018/03/22/oakworth-capital-inc-increases-stake-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.